Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine in Hereditary Spastic Paraplegia
NCT05613114Completed
- Sponsor
- European University of Lefke
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial in hereditary spastic paraplegia (HSP) comparing Dalfampridine + Physiotherapy with Placebo + Physiotherapy (2 arms). Primary endpoint: Timed 25-foot Walk Test at 8 weeks. Started Aug 2020; status: completed.
02
Drugs
dalfampridine
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on NCT05613114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613114.